A Multi-Pathway Rationale for the Next Therapeutic Current

Statement of Need

More than 40% of U.S. adults now live with obesity, and incretin-based therapies have transformed what treatment can achieve. Yet the same clinical experience that produced those gains has exposed their limits: response varies widely from patient to patient, persistence is often short, and weight is regained when effective therapy stops. Guidelines increasingly frame obesity as a chronic, relapsing disease — but many clinicians still approach it as a single problem with a single solution, and remain unfamiliar with the emerging biology, including amylin, a naturally occurring satiety hormone that regulates appetite through mechanisms distinct from GLP-1.

In this opening conversation, Lee M. Kaplan, MD, PhD, joins series chair Robert F. Kushner, MD, to make a deceptively simple case: because no single mechanism drives obesity in every patient, no single mechanism will treat it in every patient. Drawing on the logic clinicians already apply to hypertension and diabetes, Dr. Kaplan explains why a heterogeneous disease demands multiple, complementary treatment pathways — and why amylin represents a genuinely new “current” in that effort.

In the first activity of this CMEO Snack series, expert faculty will set the stage for the series: the biology of amylin, the promise of phenotype-guided care, and the emerging trial data that follow across three more expert conversations. Short, practical, and forward-looking — an essential primer for any clinician preparing for the next era of obesity care.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Identify obesity as a chronic, relapsing disease process with unmet needs that motivate multi-pathway therapeutic development

Financial Support

Supported by an educational grant from Novo Nordisk Inc.

Target Audience

Obesity medicine clinicians [physicians, nurse practitioners (NPs), physician associates (PAs), pharmacists] involved in weight management and metabolic care, including endocrinology, primary care, cardiology/metabolic clinics, and obesity medicine settings

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 0.25

CME Outfitters, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists (ACPE) 0.25

This application-based activity is approved for 0.25 contact hours (0.025 CEUs) of continuing pharmacy credit (JA0007185-0000-26-096-H01-P).

Nurses (ANCC) 0.25

This activity is designated for 0.25 contact hours.

California Residents: Provider approved by the California Board of Registered Nursing, Provider # CEP 15510, for 0.25 Contact Hours.

Physician Assistants (AAPA): 0.25

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 08/07/2027. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 0.25

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Kushner reports the following financial relationships:

Advisory Board: AbbVie Inc.; Antag Therapeutics; AstraZeneca; Boehringer Ingelheim; Currax Pharmaceuticals; Lilly; Novo Nordisk; Structure Therapeutics, Inc.; Viking Therapeutics; and Weight Watchers

Dr. Kaplan reports the following financial relationships:

Consultant: Altimmune; Amgen Inc.; AstraZeneca; Boehringer Ingelheim; Dexcel Pharma; Ethicon; Helicore Biopharma, Inc.; Kallyope Inc.; Lilly; MetaVia; Neurogastrx, Inc.; Novo Nordisk; Oxford Medical Products Limited; Perspectum; Pfizer Inc.; Prometheus Laboratories; Roche; SparkSeven Bio; State 4 Therapeutics; Structure Therapeutics, Inc.; The Last Food Fight; and Wave Life Sciences

Stock Shareholder (directly purchased): Rhythm Pharmaceuticals, Inc.

The following individuals have no financial relationships to disclose:

Jeffrey Helfand, DO (Peer Reviewer)
Shirley Michelle Franks, DNP, APRN, FNP-BC, PMC, MSN, Ed (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
Warren Beckman (Planning Committee)
Andrea Perseghin, EdD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

SN-314-080726-68

A Multi-Pathway Rationale for the Next Therapeutic Current

Faculty

Statement of Need

Learning Objectives

Financial Support

Target Audience